cycloheximide has been researched along with carfilzomib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Chen, KF; Chu, PY; Hsieh, FS; Huang, CT; Huang, TT; Hung, MH; Ko, PS; Liu, CY; Shiau, CW; Tsai, WC; Wang, WL; Yu, YB | 1 |
2 other study(ies) available for cycloheximide and carfilzomib
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Carfilzomib induces leukaemia cell apoptosis via inhibiting ELK1/KIAA1524 (Elk-1/CIP2A) and activating PP2A not related to proteasome inhibition.
Topics: Adult; Aged; Animals; Apoptosis; Autoantigens; Cell Line, Tumor; Cycloheximide; Down-Regulation; Female; HL-60 Cells; Humans; Intracellular Signaling Peptides and Proteins; K562 Cells; Leukemia; Male; Membrane Proteins; Mice, Nude; Middle Aged; Neoplasm Transplantation; Okadaic Acid; Oligopeptides; Proteasome Endopeptidase Complex; Protein Synthesis Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |